NCT04200365 - A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2020

Primary Completion Date

September 7, 2023

Study Completion Date

September 7, 2023

Conditions

Chronic Graft-versus-host-disease

Interventions

DRUG

Itacitinib

Itacitinib will be administered orally once daily for up to 24 months.

Trial Locations (5)

The Sarah Cannon Research Institute, Nashville

Texas Oncology - Sammons Cancer Center, Dallas

Texas Transplant Institute, San Antonio

South Austin Medical Center, Austin

Colorado Blood Cancer Institute, Denver